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gadolinium-based agents of different relaxivities, either in saline or iodinated carriers at 1.5, 3
and 7 T ﬁeld strengths was evaluated in vitro.
Materials and methods: At 1.5, 3.0 and 7.0 T, gadobenate and gadoteridol were studied at different
concentrations in both normal saline and iodinated contrast. IRT1W and multi-echo T2FSE
sequences were obtained. Signal–concentration relationship of both used agents in different carriers
and ﬁeld strengths was plotted from their collected T1 and T2 values, as well as their derived lon-
gitudinal (r1) and transverse (r2) relaxivities.
Results: Signiﬁcant increase in T1 signal intensity (p< 0.001) of both gadobenate and gadoteridol
was observed in higher ﬁelds of 3 T and 7 T, stronger for gadoteridol. Contrarily, gadoteridol099562; fax: +965 24825508.
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284 M.R. Nouh et al.showed a signiﬁcantly lesser decrease (p< 0.0001) of T2 signal intensity with increasing ﬁeld from
3 T to 7 T.
Iodinated carriers signiﬁcantly diminished T2 signal intensity (p< 0.0001) except for highest con-
centration (10 mmol/L) (p= 0.8899) while this was only signiﬁcant (p= 0.0279) between extreme
concentrations for T1 signal.
Conclusion: On transitioning to high-ﬁeld (3 T and 7 T) MR arthrography, keeping the least
amount of iodine for intra-articular contrast delivery, and when choice is available, gadoteridol
is preferable to gadobenate. However, gadobenate was still optimal at 3 T.
 2013 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The concentration of gadolinium utilized for MR arthrography
has been inconsistently described (1). Consequently, several
studies have attempted to optimize this concentration with var-
ious in vitro models, up to 3 T ﬁeld strength (2,3). With the clin-
ical and patient research uses of MR arthrography at even
higher ﬁeld scanner, we sought to perform a phantom study
comparing potential arthrographic concentrations of gadolin-
ium at 7 T, as compared with 1.5 T, and 3 T. In addition, we
performed this comparison utilizing saline as a carrier as well
as saline admixed with iodinated contrast media, to mimic the
two schools of direct arthrography technique (3). Lastly, as
MR contrast agent relaxivity and concentration are ﬁeld depen-
dant and directly affect the quality of the obtained image (4), we
compared two different gadolinium-based agents, of different
relaxivities evaluating both T1 and T2 weighted images.
2. Materials and methods
We compared two gadolinium-based agents of different relax-
ivities: Gadobenate dimeglumine (MULTIHANCE, Bracco
Diagnostics, Milan, Italy) with higher relaxivity and Gadoter-
idol (PROHANCE, Bracco Diagnostics, Milan, Italy) with
somewhat lower relaxivity (5). To assess MR arthrographic
concentrations at different ﬁeld strengths, we constructed a
phantom of 2.5 mL plastic tubes. Each tube contained concen-
trations of 1.25 mmol/Liter [0.25% by volume], 2.5 mmol/Li-
ter [0.5% by volume], 5.0 mmol/Liter [1.0% by volume], and
10.0 mmol/Liter [2.0% by volume] of either gadobenate or
gadoteridol diluted in pure normal saline (0.9% sodium chlo-
ride) or, 50% saline-iodinated contrast mix of normal saline
plus iodinated contrast media: Isopamidol 41% [Isovue-M
200; Bracco, Princeton, NJ] with an organic iodine content
of 200 mg/ml. We used a single iodine concentration as our
aim was to compare direct MR arthrographic enhancement
criteria of two gadolinium-based agents of different physico-
chemical properties and relaxivities. Such relatively high iodine
concentration was considered for the emerging application for
concomitant MR and CT Arthrography (6). The resulting 16
solution set was placed in sealed tubes to avoid changes in
solutions during imaging (e.g. volume and chemical changes
due to evaporation, spillage), imbedded in clay; for immobili-
zation during imaging; and then placed in a plastic container
to create the desired phantom (Fig. 1).
This contrast agent phantom was imaged on 1.5 T, 3 T and
7 T whole body MR Systems (Siemens; Erlangen, Germany)
using a head coil. The room temperature of each scanner
was adjusted to 22 C to eliminate any temperature effects.To minimize magnetic ﬁeld inhomogeneities, each magnet
was shimmed before beginning image acquisition. Addition-
ally, the phantom was imaged twice, with the second position
rotated about 180, and these signal intensities averaged.
The ﬁeld of view (FOV) was 160 · 160 mm and matrix was
256 · 256 for all sequences. Inversion recovery (IR) sequences
were used for (1) their known superior T1-contrast (2) providing
greater sensitivity in detecting gadolinium (Gd) contrast enhance-
ment and (3) reliable assessment of T1 data for examined con-
trast agent concentrations than conventional spin-echo (SE)
sequences (7,8). The parameters of used pulse sequences in cur-
rent study at different ﬁeld strengths are summarized in Table 1.
2.1. Calculation of contrast-enhanced signal for clinical imaging
The signal intensity (SI) was measured using ‘‘Image-J’’ a
Java-based image-processing package (http://rsb.info.nih.gov/
ij/) that measured area, mean, and standard deviation of signal
intensity within the central portion of each tube image avoid-
ing possible alterations of SI near the solution–tube interface.
This process had been repeated ﬁve times for each tube. Ex-
treme highest and lowest readouts were eliminated followed
by calculation of the averages of the remaining three values
of each tube. The average signal intensity of the opposite posi-
tions of the phantom for every sequence was used to mitigate
ﬁeld heterogeneity effects.
3. Statistical analysis
Analysis of variance based on ranks was used to assess the
interaction of used gadolinium-based agent (Gadobenate or
Gadoteridol), its concentration (1.25, 2.5, 5, and 10 Mmol/
L), carrier (saline or saline-iodine mix), and ﬁeld strength
(1.5 T, 3 T and 7 T) on measured average signal intensity.
Terms representing two-factor interactions were examined in
order to test whether the effect of one factor on signal intensity
varied across the levels of a second factor (e.g., whether the
inﬂuence of agent concentration on signal intensity depended
on which agent was used).
All (p) values reported are two-sided type 3 signiﬁcance lev-
els (to assess the effect of one factor adjusted for the effects of
other factors included in the model) and were considered sig-
niﬁcant when less than 0.05. SAS version 9.0 (SAS Institute,
Cary, NC) was used for all statistical computations.
4. Results
The resulting T1 and T2 values were plotted on graphs com-
paring Gadobenate and Gadoteridol concentrations to signal
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Fig. 1 Schematic representation of the phantom labeled with the contents and concentrations of the individual tubes. M stands for
gadobenate dimeglumine (Multihance), P stands for gadoteridol (Prohance) and Iod for Isopamidol 41% solutions.
Table 1 Summary of imaging parameters used at 1.5 T, 3 T and 7 T ﬁeld strengths in current study.
Sequence/Parameters IR-T1 W-SE T2 W-SE
Field strength 1.5 T 3 T 7 T 1.5 T 3 T 7 T
TR 4000 5000 6000 3000 3000 6000
TE 20 9.5 12 15,30,45,60, 75, 90, 105, 150a
TI 50,100, 200, 300,400. 50,100,200,300,
500,800,1200,2500, 3000, 4000, 5000a
a Parameter values only available on 7 T ﬁeld strength.
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as their derived longitudinal (r1) and transverse (r2) relaxivities
(Fig. 4).5. Signal intensity
5.1. 1.5T
Both gadobenate and gadoteridol showed increased T1 signal
intensity up to 5 mmol/L concentrations in saline carrier. A
slight increase in T1 signal intensity was observed for higher
concentrations of gadobenate, as opposed to a slight drop
for gadoteridol.
In iodine-saline mixes, the highest T1 W signal intensity of
both agents was observed at lower concentrations (1.25 mmol/
L) followed by a progressive decrease with increased concen-
tration (Fig. 2a and b).
On T2W sequences, both gadobenate and gadoteridol
showed a progressive decrease in signal intensity with increasing
concentration in both carriers, except at the highest concentra-
tion; 10 mmol/L; of gadobenate and 2.5 mmol/L concentration
of Gadoteridol in iodinated solutions (Fig. 3a and b).5.2. 3T
There was a linear response of T1 W signal intensity in relation
to concentrations of both gadobenate and gadoteridol in the
saline carrier with no signiﬁcant deleterious effect after admix-
ing iodine (Fig. 2c and d).On T2 W sequences, both gadobenate and gadoteridol in
saline solution behaved similarly, at 1.5 T, yet there was a
notable higher mean T2 signal intensity of gadoteridol com-
pared to gadobenate.
In iodinated solutions, gadobenate showed decreased signal
intensity, except for the 2.5 mmol/L while gadoteridol showed
a drop of signal intensity for all concentrations except
10 mmol/L where the signal intensity increased (Fig. 3c and d).
5.3. 7T
In the saline carrier, there was a non-signiﬁcant increase in
T1 W signal intensity across different concentrations for gad-
obenate, while gadoteridol showed nearly a linear response
of T1 W signal intensity for all concentrations. Similar to other
ﬁeld strengths, both agents showed a lower T1 W signal inten-
sity in iodine carriers. Interestingly, gadoteridol T1 signal was
notably higher than gadobenate. (Fig. 2e and f).
On T2 W sequences, both gadobenate and gadoteridol in
saline solution showed a progressive decrease in T2 signal, in
response to increased agent concentration. In iodinated solu-
tions gadobenate showed a similar linear response, except at
lower concentrations (1.25 and 2.5 mmol/L) where greater
changes were seen. Unexpectedly, gadoteridol showed a pro-
gressive decrease in T2 signal intensity up to 5 mmol/L then
started to rise in intensity at higher concentrations.
Of interest, the T2 signal intensity values for gadobenate
were much lower than gadoteridol at 7 T (Fig. 3e and f).
When the analysis was stratiﬁed by carrier (Fig. 4), there
was a signiﬁcant positive correlation with mean signal intensity
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Fig. 2 T1 W Signal intensity of both Gadobenate and Gadoteridol admixed with normal 0.9 Mmol/L saline and iodine, at different ﬁeld
strengths.
286 M.R. Nouh et al.in saline solutions (p= 0.0309) opposed to signiﬁcantly nega-
tive correlation to iodinated solutions (p= 0.0033).
When the analysis was stratiﬁed by concentration, changes
in T1 signal intensity with changed concentration of either
contrast agent in saline solutions were not statistically signiﬁ-
cant (p values 0.2619–0.9999) while this was signiﬁcant in
iodinated solutions for changed concentration from its lowest
(1.25 mmol/L) to its highest (10 mmol/L) levels only
(p= 0.0279). On the other hand, every change in the concen-
tration of either agent regardless of the carrier was associated
with a signiﬁcant decrease in terms of T2 signal intensity
(p< 0.0001) except for the highest concentration (10 mmol/
L) (p= 0.8899).
Considering the ﬁeld strength–signal intensity interaction
there was a statistically signiﬁcant (p< 0.001) increase in
mean T1 signal intensity for both gadobenate and gadoteridol
and this was stronger for the latter compared to the former in
higher ﬁelds of 3 T and 7 T (Fig. 5a).In terms of T2 signal intensity gadoteridol speciﬁcally
showed a signiﬁcantly lesser decrease (p< 0.0001) with increas-
ing ﬁeld from 3 T to 7 T, than did gadobenate dimeglumine.
However, at 1.5 T gadobenate had a signiﬁcantly (p= 0.003)
higher T2 signal intensity than Gadoteridol (Fig. 5b).
Overall the mean SI of both agents was increased with higher
ﬁeld strength. This was larger for gadoteridol and at 7 T (Fig. 6).
5.4. Relaxivity
Both agents exhibited positive and statistically signiﬁcant in-
creased longitudinal [(r1), p= 0.0124] and transverse [(r2),
p= 0.0118] relaxivities with increased concentration in both
used carriers (Fig. 7a and b). In spite of an apparent decrease
in r1 relaxivity at highest concentration (10 mmol/L), it was
not statistically signiﬁcant (p> 0.11).
Comparing ﬁeld strength effects, both gadobenate and gad-
oteridol showed a non-signiﬁcant difference between 1.5 T and
100
600
1100
1600
2100
2600
3100
3600
4100
Si
gn
al
 In
te
ns
ity
Concentration (mmol/L)
1.5 T/Gadoteridol T2
Saline
Iodinated
100
600
1100
1600
2100
2600
3100
3600
4100
Si
gn
al
 In
te
ns
ity
Concentration (mmol/L)
3 T/Gadoteridol T2
Saline
Iodinated
100
600
1100
1600
2100
2600
3100
3600
4100
Si
gn
al
 In
te
ns
ity
Concentration (mmol/L)
7 T/Gadoteridol T2
Saline
Iodinated
100
600
1100
1600
2100
2600
3100
3600
4100
Si
gn
al
 
in
te
n
si
ty
Concentration (mmol/L)
1.5 T/Gadobenate T2 
Saline
Iodinated
100
600
1100
1600
2100
2600
3100
3600
4100
Si
gn
al
 In
te
n
si
ty
Concentration (mmol/L)
3 T/Gadobenate T2
Saline
Iodinated
100
600
1100
1600
2100
2600
3100
3600
4100
0 1.25 2.5 3.75 5 6.25 7.5 8.75 10
0 1.25 2.5 3.75 5 6.25 7.5 8.75 10
0 1.25 2.5 3.75 5 6.25 7.5 8.75 10
0 1.25 2.5 3.75 5 6.25 7.5 8.75 10
0 1.25 2.5 3.75 5 6.25 7.5 8.75 10 0 1.25 2.5 3.75 5 6.25 7.5 8.75 10
Si
gn
al
 
In
te
n
si
ty
Concentration (mmol/L)
7 T/Gadobenate T2
Saline
Iodinated
a b
c d
e f
Fig. 3 T2 W Signal intensity of both Gadobenate and Gadoteridol admixed with normal 0.9 Mmol/L saline and iodine, at different ﬁeld
strengths.
Optimal gadolinium concentration for direct MR arthrography at high ﬁeld strength up to 7 T: 2873 T (p> 0.5) in terms of mean longitudinal relaxivity (r1) yet it
became signiﬁcantly lower (p< 0.01) at 7 T than at either
1.5 T or 3 T for both agents. (Fig. 8a)Fig. 4 Mean signal intensity for both gadobenate dimeglumine
and gadoteridol in both used carriers (saline and 50% iodine-
saline mix).In contradistinction, gadoteridol-containing solutions were
associated with a signiﬁcant decrease in T2 relaxivity (r2) re-
lated to ﬁeld strength (1.5 T to 3 T; p= 0.035 and 3 T to
7 T; p= 0.097) while there was a non-signiﬁcant (p= 0.480)
increase in case of gadobenate-containing solutions (Fig. 8b).6. Discussion
Direct MR arthrography shows an improved evaluation of
several speciﬁc articular disorders (1). The contrast medium in-
jected for MR arthrography distends and differentiates the
capsule-ligamentous complex from other articular surfaces
and outlines intra-articular structures (1,3).
The dose and concentration of the MR contrast agents as
well as their in situ relaxivities are the prime determinants of
their enhancement (4,9,10).
Our results conﬁrmed that the progressive increased T1 sig-
nal intensity of both gadobenate and gadoteridol; in saline;
seen with increased ﬁeld strength continues up to 7 T (11–13).
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Fig. 5 Mean T1 (a) and T2 (b) signal intensity changes compared to changing ﬁeld strength for gadobenate dimeglumine and
gadoteridol.
Fig. 6 The mean SI-Field strength relationship for both gadob-
enate and gadoteridol.
288 M.R. Nouh et al.Also our results conﬁrmed the concentration-dependence of
T2 SI of both agents; in saline (11,13,14). This was also pro-
nounced with increased ﬁeld strength; greatest for the gadobe-
nate at 7 T. This could be explained by faster dephasing due to
spin–spin interaction caused by higher concentrations of gad-
olinium-based agents with resultant T2 shortening expressed
as signal loss on T2 W images (11,14). Subsequently, these
spin–spin dephasing will be augmented with increased external
ﬁeld strength explaining ﬁeld strength changes at 7 T. Our data
compare well with previous reports (2,11,15–17) addressing the
relationship between gadolinium-based agents’ dose and ﬁeld
strength.Fig. 7 Relaxivity concentration relationship for saline and iodinate
(b) (r2) Relaxivity concentration relationship.Interestingly, we encountered a boosted T1 signal intensity
at the lowest concentrations of both contrast agents in iodine
carrier. This synergism could be attributed to the additive
T1 W shortening effect of iodine on T1 signal intensity (18).
Our data conﬁrm the decline of signal intensity of both used
MR contrast agents mixed with iodine on T1 W images and
more deleteriously on T2 W images, higher ﬁelds and for gad-
oteridol. These results reinforce the results of previous in vivo
(19) and in vitro reports (2,6,16,17) studying signal intensities
of iodine-gadolinium contrast mixes. While Montegomery
et al. (16) proposed that this effect could be related to an in-
crease in the viscosity or to a reduction in the proton density
of the mixture; Masi et al. (2) attributed this decline in signal
intensity to the magnetic susceptibility of iodine and they
stressed on the clarity of these ﬁndings in high ﬁeld strength
[3T in their model] more than lower one [1.5 T]. The Relaxivity
of an agent is its ability to alter the relaxation rates of the sur-
rounding substances (8,20). Thus higher relaxivity might lead
to the use of lower doses and potentially decreased toxicity (9).
Relaxivity is dependent on external ﬁeld, as well as the spe-
ciﬁc chemical make up of the contrast agent, and will vary
based on the local tissue environment (4).
We demonstrated a signiﬁcant decrease in longitudinal
relaxivity of both agents at 7 T.
These results are similar to those of Rohrer et al. (5) and
Pintaske et al. (8) although the highest ﬁeld strength studied
was 4.7 T. We however, noticed a signiﬁcantly increased con-
spicuity of both tested contrast agents as we increased ﬁeld
strength. The signal intensity of gadoteridol was signiﬁcantlyd saline solutions. (a) (r1) Relaxivity concentration relationship.
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Fig. 8 Relaxivity-ﬁeld strength relationship for gadobenate dimeglumine and gadoteridol. (a) Mean T1 relaxivity (r1) curve. (b) Mean
T2 relaxivity (r2) curve relationship.
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signal intensity in spite of decreased relaxivity could be ex-
plained by the improved signal to noise outweighing relaxivity
changes (12).
Our work revealed higher relaxivity of both used MR con-
trast agents in iodinated solutions than in pure saline. These
results are similar to those of prior authors (16,20) conﬁrming
that the mixture of iodinated and gadolinium contrast affects
the MR relaxation properties of gadolinium contrast agents
and shortens both T1 and T2, with T2 shortening being more
evident translated into signal loss.
Gadoteridol is a non-ionic, macrocyclic and non-speciﬁc
extracellular agent while gadobenate is an ionic and linear spe-
ciﬁc blood-pool agent. Several reports (5,8) have demonstrated
the high relaxivity of gadobenate compared to gadoteridol.
This improvement in the relaxivity depends on the carrier as
well as rotational dynamics (5). Previous work has emphasized
that stated relaxivity values are not necessarily an accurate
reﬂection of the efﬁciency of the contrast agent, especially
for agents, which bind to albumin in vivo as gadobenate in
our in vitro model (4,5).
Our in vitro study is limited as our model did not have the
same chemical composition as synovial ﬂuid. Another limita-
tion is the limited number of concentrations we evaluated.
Also, we tested a single concentration of iodinated contrast
media although the amount of iodinated contrast used during
the arthrographic procedure may vary depending on the skills
and preference of the arthrographer.
In conclusion, on transitioning to high-ﬁeld [3 T and 7 T]MR
arthrography, our results suggest decreasing concentration of
used gadolinium-based agent alongwithminimizing the amounts
of iodinated-contrast agents used to conﬁrm intra-articular con-
trast delivery, to avoid a decrease in signal onT2 sequences.When
choice is available gadoteridol is preferable to gadobenate at 3 T
and 7 T. However, gadobenate was more optimal at 3 T.
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